Biomarker-Guided therapy aims to cut stroke risk in heart rhythm patients
NCT ID NCT03753490
Summary
This study is testing whether personalized treatment decisions based on blood biomarker risk scores can better prevent strokes or death in people with atrial fibrillation compared to standard care. About 6,500 patients with this heart rhythm condition will be randomly assigned to receive either biomarker-guided therapy or usual treatment. The goal is to see if this personalized approach improves outcomes while managing bleeding risks.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ATRIAL FIBRILLATION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Uppsala University Hospital
Uppsala, Sweden
Conditions
Explore the condition pages connected to this study.